Cpl Life Sciences US

We would like to wish Tom Hancox, Vice President at Cpl Life Sciences US a very #happybirthday and we hope you've enjoyed your birthday day off! 🥳 🎂 #Cpl #workthefuture #birthdaywishes

Happy Thanksgiving from Cpl Life Sciences US! 🦃🍂   As we reflect on the past year, we want to take a moment to express our deepest gratitude to all of our clients, partners, and the incredible professionals we work with every day. Your trust, collaboration, and dedication make all the difference, and we are truly thankful for the opportunity to be a part of your journey in life sciences. We're proud to be a part of a community that's making a meaningful impact on healthcare and scientific advancement.   From all of us at Cpl Life Sciences US, we wish you and your loved ones a safe, joyful, and peaceful holiday. May this season bring you warmth, happiness, and many reasons to be thankful. Happy Thanksgiving! 🍁 #ThanksGiving

💡 Meanwhile, in major pharmaceutical news...What's the future of healthcare? 👩🔬 After launching several new, effective medicines and vaccines this year, Paul Hudson and his team at Sanofi have also received regulatory approval for a new treatment in lung disease. 🤖 Amongst these developments, they have also launched Modulus, a new type of AI powered factory that produces multiple vaccines and medicines at a faster rate which will only help the response time for future health crises. As Sanofi looks to focus on developing new medicines and treatments, they look to capitalize on becoming a pure-play biopharma organization by spinning off its consumer health business. 🔬 What does this mean for the industry...? - Innovation: They are leading the way in medicine manufacturing with AI, bringing a positive sign for the industry. - Patient Access: They are improving the health and well-being of millions as they strive for groundbreaking new treatments. - Industry Consolidation: Sanofi's decision to focus solely on biopharma could lead further organizations to specialize and focus on their core competencies. ⁉ What other impacts can you see Sanofi having on the industry? Is Big Biotech on the way? What are you most excited about in the future of healthcare? 🗯 Share your thoughts below! #HealthcareFuture, #Innovation, #PatientCentered

Congratulations to Tom Hancox who is celebrating his work anniversary with us today! 🎉 Thank you for all your valuable contributions to the company and successes! 👏 #thankyou #kudos #success #workanniversary

We'd like to wish our colleague Christopher Jimenez who celebrated his birthday in August a very #happybirthday, and we hope you enjoyed your birthday day off! 🥳 🎂 #Cpl #workthefuture #birthdaywishes

❗ Exciting Times for Ascendis Pharma as they Secure FDA Approval for Yorvipath After a Long Road of Challenges! 👍 Ascendis Pharma’s recent FDA approval for Yorvipath (palopegteriparatide), its breakthrough hormone replacement therapy for hypoparathyroidism, marks a significant milestone not just for the company, but for the entire pharmaceutical industry. The approval, following a challenging 15-month delay, underscores the company’s resilience and commitment to advancing healthcare in rare disease treatment. Ascendis Pharma’s perseverance in overcoming regulatory hurdles highlights the need for skilled professionals who can navigate complex challenges in drug development and regulatory affairs. As Yorvipath prepares for its U.S. launch, the company will likely seek to expand its teams in manufacturing, quality control, regulatory compliance, and commercialization to ensure a successful rollout. “We have worked on this product for nearly 10 years,” Ascendis CEO Jan Møller Mikkelsen said during a conference call Monday. This decade-long commitment reflects the dedication and resilience of the Ascendis team in their mission to deliver life-changing therapies to patients in need. Despite the setbacks, the company remained focused, and now the finish line is finally in sight. This approval is a beacon of hope for the estimated 70,000 to 90,000 people in the U.S. suffering from hypoparathyroidism, a condition that disrupts the body’s delicate balance of calcium and phosphorus. Yorvipath, offering continuous 24-hour dosing, demonstrated its effectiveness in clinical trials by significantly improving calcium levels and reducing the need for conventional therapies. 💡 For Ascendis Pharma this is a story of innovation, resilience, and hope for patients with unmet medical needs. We are grateful for the advancements in technology that make such breakthroughs possible and look forward to seeing Yorvipath transform lives in the near future. [Read the full article here] https://lnkd.in/ehyhYkcA ❓ As we witness these exciting developments in the industry, what do you think will be the key factors for success in launching innovative therapies like Yorvipath? Whether you’re a seasoned professional or just starting in the pharma and biotech fields, I’d love to hear your insights. Let’s discuss how these trends might shape the future of our industry and the opportunities they create for top talent. #PharmaIndustry #Biotech #DrugDevelopment #ClinicalOperations #Regulatory #PharmaceuticalNews

❤️ Heart Care Revolution! Huge Achievements have been reached with the First Successful Implantation of BiVACOR's Total Artificial Heart (TAH). We are thrilled to share a groundbreaking achievement in the field of cardiac care! The Texas Heart Institute and BiVACOR have successfully implanted the BiVACOR Total Artificial Heart (TAH) in a human for the first time. This innovative device, designed to replace both ventricles of a failing heart, represents a beacon of hope for patients with severe heart failure awaiting transplants. 👩🔬 This milestone not only showcases the incredible advancements in med tech but also brings us one step closer to providing life-saving solutions for countless individuals. The BiVACOR TAH, with its advanced design and magnetic levitation technology, promises to transform the future of heart failure therapy. We are immensely proud of the dedicated teams at The Texas Heart Institute, BiVACOR, Baylor College of Medicine, and CHI St. Luke's Health - Baylor St. Luke's Medical Center for their unwavering commitment to improving patient outcomes. Together, they are pioneering a new era in cardiac medicine and offering renewed hope to those in need. 🗓 This is a huge testament to why our industry work is so rewarding and how leveraging partnerships can speed up timelines for patients who need it most, AMAZING WORK! #Innovation #Healthcare #MedicalBreakthrough #HeartFailure #CardiacCare #Biotechnology" Read more below and share your thoughts! https://lnkd.in/dRiUxxPw

We love receiving candidate feedback. Here is an amazing review Aoife Gillespie has recently received! We love hearing about our candidate success stories and placing them into their dream roles within industry. Wishing each and every one of our candidates the best of luck in their new roles! 🌟 #feedbackmatters #testimonial #kudos

In our latest case study, we delve into how CPL Life Sciences US has revolutionized talent acquisition for our clients. Our client, a leading firm in the industry, shares their experience: "What has impressed us is the diversity of candidates Cpl seems to send across. Shortlists tend to have a mixture of backgrounds and skillsets, which is positively recognized internally." Explore how our commitment to diversity and inclusion not only meets but exceeds expectations, providing a rich pool of talent that drives innovation and success. Learn about our strategic approach, unique methodologies, and the tangible benefits our clients experience by partnering with Cpl Life Sciences US. Read the full case study to see how we can transform your talent acquisition process! https://lnkd.in/gZSr2V_B #LifeSciences #CaseStudy

Happy 4th of July to all our clients and candidates in the USA! May this Independence Day be filled with pride, unity, and joy as we celebrate the spirit of freedom and democracy. Tom Hancox Aoife Gillespie Christopher Jimenez Rhys Rowberry #IndependenceDay #LifeSciences #4thofJuly